Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vaginal Lymphoma: A Possible Cause of Genital Hemorrhage.
Nohuz E, Kullab S, Ledoux-Pilon A, Moluçon-Chabrot C, Albaut M, De Simone L, Durando X. Nohuz E, et al. Turk J Haematol. 2016 Sep 5;33(3):259-60. doi: 10.4274/tjh.2015.0112. Epub 2016 Apr 18. Turk J Haematol. 2016. PMID: 27094853 Free PMC article. No abstract available.
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C. Ghesquieres H, et al. Ann Oncol. 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032. Ann Oncol. 2019. PMID: 30698644 Free article. Clinical Trial.
Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau MP, Moluçon-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP, Fabbro M, Naudet F, Hoang-Xuan K, Houot R. Langner-Lemercier S, et al. Neuro Oncol. 2016 Sep;18(9):1297-303. doi: 10.1093/neuonc/now033. Epub 2016 Mar 6. Neuro Oncol. 2016. PMID: 26951382 Free PMC article.
Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.
Bahashwan S, Moluçon-Chabrot C, Hermet E, Ravinet A, Douge A, Veronese L, Tchirkov A, Lemal R, Berger MG, Veyrat-Masson R, Tournilhac O, Bay JO, Guièze R. Bahashwan S, et al. Am J Hematol. 2019 Jan;94(1):E32-E35. doi: 10.1002/ajh.25332. Epub 2018 Nov 25. Am J Hematol. 2019. PMID: 30370957 Free article. No abstract available.
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.
Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma. Houillier C, et al. J Clin Oncol. 2019 Apr 1;37(10):823-833. doi: 10.1200/JCO.18.00306. Epub 2019 Feb 20. J Clin Oncol. 2019. PMID: 30785830 Clinical Trial.
[Major therapeutic advances and new perspectives in onco-hematology].
Bay JO, Guièze R, Ravinet A, Lemal R, Xhaard A, Bailly S, Moluçon-Chabrot C, Hermet E, Biau J, Verrelle P, Peffault de Latour R, Tournilhac O. Bay JO, et al. Bull Cancer. 2013 Jun;100(6):587-99. doi: 10.1684/bdc.2013.1751. Bull Cancer. 2013. PMID: 23735575 Review. French.
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Letestu R, Dahmani A, Boubaya M, Baseggio L, Campos L, Chatelain B, Debliquis A, Drénou B, Jacob MC, Legac E, Le Garff-Tavernier M, Lhoumeau AC, Quiney C, Robillard N, Ticchioni M, Aanei C, Katsahian S, Delepine R, Vaudaux S, Rouillé V, Béné MC, Dartigeas C, Van Den Neste E, Leprêtre S, Feugier P, Cartron G, Leblond V, Lévy V, Cymbalista F; French Innovative Leukemia Organization (FILO). Letestu R, et al. Leukemia. 2021 Jun;35(6):1597-1609. doi: 10.1038/s41375-020-01009-z. Epub 2020 Sep 15. Leukemia. 2021. PMID: 32934355
Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study.
Lesueur P, Damaj G, Hoang-Xuan K, Roland V, Schmitt A, Chinot O, Fabbro M, Agapé P, Moluçon-Chabrot C, Chebrek S, Alentorn A, Feuvret L, Delgadillo D, Stefan D, Choquet S, Nichelli L, Mokhtari K, Mathon B, Dureau S, Soussain C, Houillier C. Lesueur P, et al. Among authors: molucon chabrot c. Blood Adv. 2022 Aug 23;6(16):4807-4815. doi: 10.1182/bloodadvances.2022007011. Blood Adv. 2022. PMID: 35772168 Free PMC article.
[Lymphoma and arteries: peri- or intravascular?].
Franz M, Alfidja A, Molucon Chabrot C, Hermet E, Montoriol PF, Rosset E, Boyer L, Chabrot P. Franz M, et al. J Mal Vasc. 2013 May;38(3):162-71. doi: 10.1016/j.jmv.2013.01.008. Epub 2013 Mar 7. J Mal Vasc. 2013. PMID: 23473620 French.
33 results